|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||113.25 - 113.88|
|52 Week Range||93.92 - 114.82|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.48%|
In 1928, Congress passed a joint resolution establishing Child Health Day, the express purpose of which was to raise awareness “of the fundamental necessity of a year-round program to protect and develop ...
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
The Cardiovascular and Metabolic Disease (or CVMD segment) contributed ~35.1% of total revenues for AstraZeneca (AZN) in 2Q17.
Bristol-Myers Squibb (BMY) surpassed Wall Street analysts’ estimate for 2Q17 revenues, reporting $5.14 billion compared to the estimate of $5.09 billion.
AstraZeneca (AZN) is one of the largest pharmaceutical companies by revenue. The company operates in over 100 countries and deals with primary care and specialty care medicines.
As discussed earlier, Johnson & Johnson’s (JNJ) 2Q17 performance was positive across all three of its segments. Let’s look at major developments for the company in 2Q17. On July 13,…
Allergan's International segment reported revenues of $737.3 million for 1Q17, which was 9.5% higher than the $673.3 million it reported in 1Q16.
Bristol-Myers reported a net profit of ~$1.57 billion in 1Q17—compared to $1.19 billion in 1Q16. Analysts expect a net profit of $1.18 billion during 2Q16.
Elanco's 1Q17 revenues include revenues from the acquired Novartis Animal Health products. The US Animal Health franchise reported growth of 5% in its 1Q17 revenues to $413.8 million.
The Cardiovascular and Metabolic Disease (or CVMD) segment contributed ~33% of AstraZeneca's (AZN) total revenue in 1Q17.
AstraZeneca’s (AZN) business is separated into four segments: Respiratory, Cardiovascular and Metabolic Diseases (or CVMD), Oncology, and Other.
Merck's (MRK) Animal Health segment operates in more than 140 countries worldwide. Global sales in 1Q17 were $939.0 million, a 13.0% rise from 1Q16.
Allergan (AGN) is set to release its 1Q17 earnings on May 9, 2017. Analysts’ estimates show EPS at $3.30 on revenues of $3.53 billion for 1Q17.
For the European markets, GSK's revenues are expected to grow in 1Q17, mainly due to increase in sales of wellness products like Voltaren and the Sensodyne products portfolio.
Bristol-Myers Squibb is set to release its 1Q17 earnings on April 27, 2017. Analysts expect EPS (earnings per share) of $0.74 and revenue of $4.7 billion for the company in 1Q17.